Literature DB >> 8112371

A comparative assessment of amlodipine and felodipine ER: pharmacokinetic and pharmacodynamic indices.

A D Bainbridge1, O Herlihy, P A Meredith, H L Elliott.   

Abstract

This study investigated potential therapeutic differences between Amlodipine 5 mg and Felodipine ER 10 mg in 12 normotensive/borderline hypertensive subjects by comparison of the plasma drug concentration-time profiles and the blood pressure and heart rate responses. There was significantly less trough-to-peak variability in plasma drug concentrations with amlodipine with a ratio of 67%, compared to 37% for felodipine. Correspondingly there was less variability with amlodipine in the blood pressure reductions across the dosage interval. Overall, amlodipine displayed a more consistent hypotensive effect across 24 hours and lower blood pressure values at trough, i.e. 24 hours post-dose.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8112371     DOI: 10.1007/bf00315513

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  Plasma concentration--effect relationships for felodipine: a meta analysis.

Authors:  E Blychert; B Edgar; D Elmfeldt; T Hedner
Journal:  Clin Pharmacol Ther       Date:  1992-07       Impact factor: 6.875

Review 2.  Some problems with antihypertensive drug studies in the context of the new guidelines.

Authors:  M Rose; F G McMahon
Journal:  Am J Hypertens       Date:  1990-02       Impact factor: 2.689

3.  Analysis of amlodipine in human plasma by gas chromatography.

Authors:  A P Beresford; P V Macrae; D A Stopher; B A Wood
Journal:  J Chromatogr       Date:  1987-09-04

4.  The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily.

Authors:  J K Faulkner; D McGibney; L F Chasseaud; J L Perry; I W Taylor
Journal:  Br J Clin Pharmacol       Date:  1986-07       Impact factor: 4.335

5.  Antihypertensive and metabolic effects of long-term therapy with nifedipine slow-release tablets.

Authors:  K Landmark
Journal:  J Cardiovasc Pharmacol       Date:  1985 Jan-Feb       Impact factor: 3.105

Review 6.  Clinical pharmacokinetics of amlodipine.

Authors:  P A Meredith; H L Elliott
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

7.  Nifedipine: individual responses and concentration-effect relationships.

Authors:  R Donnelly; H L Elliott; P A Meredith; A W Kelman; J L Reid
Journal:  Hypertension       Date:  1988-10       Impact factor: 10.190

8.  Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans.

Authors:  C H Kleinbloesem; P van Brummelen; M Danhof; H Faber; J Urquhart; D D Breimer
Journal:  Clin Pharmacol Ther       Date:  1987-01       Impact factor: 6.875

9.  Felodipine pharmacokinetics and plasma concentration vs effect relationships.

Authors:  E Blychert
Journal:  Blood Press Suppl       Date:  1992

10.  Pharmacodynamic modeling of the antihypertensive response to amlodipine.

Authors:  R Donnelly; P A Meredith; S H Miller; C A Howie; H L Elliott
Journal:  Clin Pharmacol Ther       Date:  1993-09       Impact factor: 6.875

View more
  7 in total

Review 1.  Pharmacokinetics as an aid to optimising compliance with medications.

Authors:  P Rudd; L Lenert
Journal:  Clin Pharmacokinet       Date:  1995-01       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of nifedipine. Implications for the care of the elderly.

Authors:  H L Elliott; P A Meredith
Journal:  Drugs Aging       Date:  1997-12       Impact factor: 3.923

3.  Lacidipine: effects on vascular pressor responses throughout the dosage interval in normotensive subjects.

Authors:  S Ueda; R Donnelly; V Panfilov; A D Morris; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

Review 4.  The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties.

Authors:  J S Grundy; R T Foster
Journal:  Clin Pharmacokinet       Date:  1996-01       Impact factor: 6.447

Review 5.  Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease.

Authors:  M Haria; A J Wagstaff
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

6.  Medication adherence during laboratory workup for primary aldosteronism: pilot study.

Authors:  Friederike A Sandbaumhüter; Manuel Haschke; Bruno Vogt; Jürgen M Bohlender
Journal:  Patient Prefer Adherence       Date:  2018-11-19       Impact factor: 2.711

Review 7.  Review of nifedipine GITS in the treatment of high risk patients with coronary artery disease and hypertension.

Authors:  Amber Lundy; Nahla Lutfi; Cherylyn Beckey
Journal:  Vasc Health Risk Manag       Date:  2009
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.